<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04605484</url>
  </required_header>
  <id_info>
    <org_study_id>P-105-201</org_study_id>
    <nct_id>NCT04605484</nct_id>
  </id_info>
  <brief_title>Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia</brief_title>
  <official_title>Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled, Multiple Dosing Interval, 3-period Study of the Safety, Tolerability and Effectiveness of Adoptively Transferred ALVR105 (Viralym-M) Multivirus-specific T Cells in Kidney Transplant Recipients With Either High or Low Levels of BK Viremia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AlloVir</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AlloVir</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare Posoleucel (formerly known as ALVR105; Viralym-M) to&#xD;
      placebo in kidney transplant recipients who have high or low levels of BK virus in their&#xD;
      blood.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 22, 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>24 weeks</time_frame>
    <description>Patients will be monitored for adverse events following each infusion and during the dosing period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in BK viremia, Posoleucel (ALVR105) compared to placebo</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in BK viral load in patients receiving Posoleucel (ALVR105) compared to patients receiving placebo, based on mean +/- standard deviation of BK viral load as determined by the BK viral load assay performed at the central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BK viremia, different dose regimens of Posoleucel (ALVR105) compared to placebo</measure>
    <time_frame>24 weeks</time_frame>
    <description>Difference in mean BK viral load +/- standard deviation in Cohort A Arm 1 versus placebo Arm 3, as compared to the difference in mean BK viral load in Cohort A Arm 2 versus placebo Arm A3, as well as the difference in mean BK viral load between Posoleucel (ALVR105) arm and the placebo arm in Cohort B-all as determined by the BK viral load assay performed at the central laboratory.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>BK Virus Nephropathy</condition>
  <condition>BK Virus Infection</condition>
  <arm_group>
    <arm_group_label>Posoleucel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort A, Arm 1: Regimen A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Posoleucel and Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort A, Arm 2: Regimen B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort A, Arm 3: Regimen A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B, Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following interim analysis, optimal posoleucel dosing regimen from Cohort A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B, Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Same dosing interval as Cohort B, Arm 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Posoleucel (formerly known as ALVR105; Viralym-M) cells</intervention_name>
    <description>Infusion</description>
    <arm_group_label>Cohort B, Arm 1</arm_group_label>
    <arm_group_label>Posoleucel</arm_group_label>
    <arm_group_label>Posoleucel and Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo (visually identical to Posoleucel)</intervention_name>
    <description>Infusion</description>
    <arm_group_label>Cohort B, Arm 2</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Posoleucel and Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who had a kidney transplant performed greater than or equal to 28 days prior&#xD;
             to enrollment&#xD;
&#xD;
          -  At least 1 identified, suitably matched Posoleucel (Viralym-M) cell line for infusion&#xD;
             is available. (If a matching Posoleucel (Viralym-M) line is not available, the&#xD;
             following patient data will be collected:&#xD;
&#xD;
        demographic data and human leukocyte antigen [HLA] type.)&#xD;
&#xD;
          -  Capable of giving signed informed consent which includes compliance with the&#xD;
             requirements and restrictions listed in the informed consent form (ICF) and in the&#xD;
             protocol.&#xD;
&#xD;
          -  Contraceptive use by men and women should be consistent with local regulations&#xD;
             regarding the methods of contraception for those participating in clinical studies.&#xD;
&#xD;
          -  A female patient is eligible to participate if she is not pregnant or breastfeeding,&#xD;
             and 1 of the following conditions applies:&#xD;
&#xD;
               -  She is a woman of non-childbearing potential (WONCBP) as defined in the protocol&#xD;
&#xD;
               -  She is a woman of childbearing potential (WOCBP) and using an acceptable&#xD;
                  contraceptive method as described in the protocol during the study treatment&#xD;
                  period and for at least 90 days after the last dose of study treatment. The&#xD;
                  Investigator should evaluate the potential for contraceptive method failure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Undergone allogeneic hematopoietic cell transplantation&#xD;
&#xD;
          -  Evidence or history of graft versus host disease (GVHD) or cytokine release syndrome&#xD;
             (CRS).&#xD;
&#xD;
          -  Uncontrolled or progressive bacterial or fungal infections&#xD;
&#xD;
          -  Known or presumed pneumonia&#xD;
&#xD;
          -  Ongoing therapy with high-dose systemic corticosteroids (ie, prednisone dose &gt;0.5&#xD;
             mg/kg/day or equivalent).&#xD;
&#xD;
          -  Pregnant or lactating or planning to become pregnant.&#xD;
&#xD;
          -  Weight &lt;40 kg.&#xD;
&#xD;
          -  Patients who received, or planned to receive abatacept, belatacept, sirolimus or&#xD;
             everolimus within 3 months of screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesca Cardarelli, MD</last_name>
    <role>Study Director</role>
    <affiliation>AlloVir</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kenny Kamineni</last_name>
    <phone>833-409-2281</phone>
    <email>clinicaltrials@allovir.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Keck Medical Center of USC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern University Transplant Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Indiana University Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kansas Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tulane University School of Medicine</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>John Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Harvard Medical School - Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UPMC Pinnacle-Harrisburg Hospital</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UPMC Montefiore Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Medical Center</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Tzannou I, Papadopoulou A, Naik S, Leung K, Martinez CA, Ramos CA, Carrum G, Sasa G, Lulla P, Watanabe A, Kuvalekar M, Gee AP, Wu MF, Liu H, Grilley BJ, Krance RA, Gottschalk S, Brenner MK, Rooney CM, Heslop HE, Leen AM, Omer B. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2017 Nov 1;35(31):3547-3557. doi: 10.1200/JCO.2017.73.0655. Epub 2017 Aug 7.</citation>
    <PMID>28783452</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 15, 2020</study_first_submitted>
  <study_first_submitted_qc>October 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2020</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Viremia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

